We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Beyond Picky Eating: Large-Scale Study Reveals the Genetic Architecture and Developmental Impact of ARFI Phenotypes

MedXY Editorial Team•Jan 6, 2026•news
ARFIDneurodevelopment

Introduction: Redefining Restrictive Eating in Pediatrics

Avoidant/Restrictive Food Intake Disorder (ARFID) represents a significant shift in how clinicians view restrictive eating behaviors. Unlike traditional eating disorders such as anorexia nervosa or bulimia nervosa, ARFID is characterized by an avoidance or restriction of food intake that is not driven by body image distortion or a desire for weight loss. Instead, it is typically motivated by sensory sensitivity, a lack of interest in eating, or fear of aversive consequences like choking. Despite its inclusion in the DSM-5, our understanding of its prevalence in the general population, its developmental trajectory, and its underlying biological mechanisms has remained limited. A groundbreaking study by Bjørndal and colleagues, published in JAMA Pediatrics, provides the most comprehensive look to date at the prevalence, characteristics, and genetic architecture of avoidant/restrictive food intake (ARFI) phenotypes.

The MoBa Study: Mapping the ARFI Landscape

This research utilized data from the Norwegian Mother, Father, and Child Cohort Study (MoBa), a massive population-based project following children born between 1999 and 2009. The researchers analyzed a sample of 35,751 children, using mother-reported data at ages 3 and 8 years, and linked this information with diagnostic data from national health registries.

To capture the full spectrum of the condition, the study defined two main tiers of the phenotype:

1. ARFI-broad: Children exhibiting a narrow range of food consumption or restricted eating patterns.
2. ARFI-clinical: A subset of the broad group who also displayed markers of clinical significance, such as nutritional deficiency, interference with psychosocial functioning, or the need for nutritional supplements.

Furthermore, the researchers categorized children based on the persistence of symptoms: transient (present only at age 3), emergent (present only at age 8), and persistent (present at both ages). This longitudinal approach allowed for a nuanced understanding of how restrictive eating evolves during early childhood.

Prevalence and Developmental Trajectories

The findings reveal that ARFI is far more common in the general pediatric population than previously estimated. Among the 35,751 children studied, the prevalence of the ‘ARFI-broad’ phenotype was substantial: 17.7% were transient, 8.4% were emergent, and 6.0% were persistent.

When applying stricter clinical criteria, the prevalence of ‘ARFI-clinical’ was 6.3% overall. Specifically, 3.2% were transient, 1.4% were emergent, and 1.8% were persistent. These figures suggest that while many children may experience phases of picky eating, a significant minority—nearly 2% of the population—struggles with a persistent, clinically significant form of restrictive eating that lasts throughout early and middle childhood.

Unmasking the Genetic Architecture

One of the study’s most significant contributions is its exploration of the genetic underpinnings of ARFI. Using genome-wide association analyses, the researchers estimated the single-nucleotide variant heritability (SNV-h2) of ARFI phenotypes to be between 8% and 16%. This confirms that restrictive eating behaviors are not merely products of the environment or parenting styles but have a clear biological basis.

Table 2. Avoidant/Restrictive Food Intake (ARFI) Symptoms and Clinical Significance Indicators in Children With Persistent, Transient, and Emergent ARFI.

Symptom No. (%)
ARFI–broad persistent (n = 2129 [5.96%]) ARFI–broad transient (n = 6338 [17.73%]) ARFI–broad emergent (n = 3001[8.39%])
ARFI symptoms: age 3 y
Does not eat well 608 (28.56) 1070 (16.88) NA
Not happy eating food 214 (10.05) 400 (6.31) NA
Fussy 1281 (60.17) 2402 (37.90) NA
Careful to make sure child eats enough 572 (26.87) 1306 (20.61) NA
If child says not hungry, try to get him/her to eat 767 (36.03) 3069 (48.42) NA
Child needs guidance or regulation to eat enough 758 (35.60) 1597 (25.20) NA
ARFI symptoms: age 8 y
Does not enjoy tasting new foods 600 (28.18) NA 422 (14.06)
Gets full easily 432 (20.29) NA 470 (15.66)
Eats slowly 615 (28.89) NA 813 (27.09)
Takes more than 30 min to finish meal 88 (4.13) NA 63 (2.10)
Gets full before finished meal 311 (14.61) NA 448 (14.93)
Does not enjoy a variety of foods 656 (30.81) NA 461 (15.36)
Is not interested in tasting new food 811 (38.09) NA 689 (22.96)
Eats less when upset 190 (8.92) NA 456 (15.19)
Leaves food on plate at the end of a meal 297 (13.95) NA 335 (11.16)
Eats less when angry 231 (10.85) NA 482 (16.06)
Clinical significance indicators
Any clinical indicator (ARFI-clinical) 624 (29.31) 1157 (18.25) 484 (16.13)
Type of clinical indicator
Weight loss/failure to growa 481 (22.59) 943 (14.88) 363 (12.10)
Nutritional deficiencyb 138 (6.48) 232 (3.66) 110 (3.67)
Clinical diagnosis of eating disorderc 152 (7.14) 105 (1.66) 61 (2.03)

The analysis identified two independent genome-wide significant loci. Most notably, a strong association was found with the ADCY3 (Adenylate Cyclase 3) locus (z = 5.42; P = 3.03 × 10−8) for the ARFI-clinical phenotype. ADCY3 is known to be involved in the regulation of appetite and energy homeostasis, and variants in this gene have previously been linked to obesity and type 2 diabetes. Its identification in the context of ARFI suggests a shared biological pathway between restrictive eating and broader metabolic regulation.

Figure 1. Developmental Characteristics for Children With and Without Avoidant/Restrictive Food Intake (ARFI) Phenotypes (N = 35 751).

Figure 1.

Furthermore, the study quantified genetic correlations between ARFI and other phenotypes. Small to moderate genetic correlations were found with mental health conditions (such as ADHD and autism spectrum disorder), cognitive/educational outcomes, anthropometric traits (BMI), and gastrointestinal disorders. This suggests that the genetic risk for ARFI overlaps with the genetic architecture of neurodevelopmental and metabolic health.

Neurodevelopmental and Clinical Correlates

The longitudinal data allowed the researchers to examine how ARFI relates to a child’s broader development. Children in the persistent ARFI-broad group exhibited significantly more developmental difficulties compared to their peers without ARFI. These difficulties were evident as early as 6 months of age and persisted through 14 years.

Affected children were more likely to show delays or challenges in motor skills, social communication, and cognitive functioning. The strong association with neurodevelopmental traits suggests that for many children, ARFI is not an isolated eating behavior but rather one manifestation of a broader neurodivergent profile. This aligns with clinical observations that ARFID is highly comorbid with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).

Expert Commentary: Clinical Implications

The implications of this study for pediatricians and mental health professionals are profound. First, the 6.3% prevalence rate of clinical ARFI underscores the need for routine screening in primary care settings. Clinicians should be mindful that persistent restrictive eating is often associated with broader developmental risks.

Second, the discovery of the ADCY3 association and the heritability of the trait should help reduce the stigma often felt by parents. Rather than viewing restrictive eating solely as a behavioral or parenting issue, it should be recognized as a complex phenotype with a significant genetic component. This biological perspective may pave the way for more targeted pharmacological or behavioral interventions in the future.

Finally, the study highlights the importance of ‘persistence’ as a clinical red flag. While transient picky eating is common, children whose symptoms persist from age 3 to age 8 are at the highest risk for long-term developmental difficulties and should be prioritized for comprehensive multidisciplinary assessment.

Conclusions and Future Directions

This landmark study clarifies that ARFI is a prevalent and clinically significant condition within the pediatric population. By identifying the genetic architecture and developmental trajectories of ARFI, the researchers have provided a foundation for future precision medicine approaches. The findings suggest that interventions should not only focus on expanding a child’s diet but also provide broad support for associated neurodevelopmental and gastrointestinal challenges. Future research should continue to explore the functional role of ADCY3 in restrictive eating and investigate whether early interventions can alter the developmental trajectory of children with persistent ARFI phenotypes.

Funding and ClinicalTrials.gov

This study was supported by grants from the Research Council of Norway and the South-Eastern Norway Regional Health Authority. Data originated from the Norwegian Mother, Father, and Child Cohort Study (MoBa). The study was preregistered on the Open Science Framework.

References

1. Bjørndal LD, Corfield EC, Hannigan LJ, et al. Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes. JAMA Pediatr. 2026;180(1):45-55. doi:10.1001/jamapediatrics.2025.4786 IF: 18.0 Q1 B1.2. Bryant-Waugh R. Avoidant restrictive food intake disorder: an illustrative case example. Clin Child Psychol Psychiatry. 2013;18(4):489-496.
3. Grilo CM. Avoidant/restrictive food intake disorder (ARFID) at age 7 years in a nationwide cohort: prevalence, co-occurrence, and risk factors. Z Kinder Jugendpsychiatr Psychother. 2021;49(4):284-290.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evaluating Neurodevelopmental Outcomes Following Intrapartum Azithromycin Administration in Neonates with Birth Asphyxia: Insights from the A-PLUS Follow-Up StudyA multicountry follow-up study found no significant improvement in neurodevelopmental outcomes at two years in infants with birth asphyxia whose mothers received a single 2 g oral dose of azithromycin during labor versus placebo.Sep 8, 2026Impact of Gestational Age and Fetal Size on Neurodevelopment from Infancy through AdolescenceThis study reveals that among term births, fetal size at birth more strongly predicts long-term neurodevelopmental outcomes than gestational age, with small-for-gestational-age infants demonstrating persistent academic challenges into adoleAug 28, 2026Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort StudyElevated maternal third-trimester TRAb levels in Graves’ disease are linked to neonatal thyroid dysfunction and impaired neurodevelopment at 24 months, independent of neonatal thyroid status, highlighting the need for prenatal monitorAug 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Child Neurodevelopmental Outcomes After Late Preterm HypoglycemiaThis study found no association between neonatal hypoglycemia in late preterm infants and adverse neurodevelopmental outcomes at age 6 years or older.Aug 18, 2026
Neurodevelopmental Outcomes of Children Conceived Post-Hysterosalpingography With Iodinated Contrast: A Critical Cohort AnalysisThis cohort study assesses the influence of hysterosalpingography with iodinated contrast on neurodevelopmental outcomes in children, revealing lower IQ scores in those conceived shortly after the procedure, warranting further investigationJul 12, 2026
Retinal Nerve Fiber Layer Thickness at 36 Weeks May Help Predict 2-Year Neurodevelopment in Very Preterm InfantsIn very preterm infants, thicker retinal nerve fiber layer on OCT at 36 weeks’ postmenstrual age was associated with better motor and cognitive outcomes at 2 years, supporting retinal imaging as a potential early neurodevelopmental biomarkeJun 8, 2026